Psoriasis
News from the FDA/CDC
FDA approves Yuflyma as ninth adalimumab biosimilar
The manufacturer Celltrion is also seeking an interchangeability designation from the FDA, tentatively expected in the fourth quarter of 2024.
Original Research
An Evaluation of Spin in the Abstracts of Systematic Reviews and Meta-analyses on the Treatment of Psoriasis: A Cross-sectional Analysis
Spin is a way of reporting that distorts the true findings; we sought to investigate the prevalence of spin in systematic review abstracts on...
News from the FDA/CDC
FDA approves autoinjector pen for Humira biosimilar, Cyltezo
The drug will be commercially available on July 1, 2023.
Feature
Axial spondyloarthritis versus axial psoriatic arthritis: Different entities?
Features of axial psoriatic arthritis and axial spondyloarthritis overlap, but whether they’re different diseases or on the same spectrum is...
Latest News
COVID-19 and psoriasis: Is there a link?
“Infection with COVID-19 has been associated with flares of guttate and pustular psoriasis, and even psoriasis that affects 100% of the skin.”
Feature
Researchers seek to understand post-COVID autoimmune disease risk
Three large studies link past SARS-CoV-2 infection to new-onset autoimmune disease, but it is not yet clear what drives this relationship.
Conference Coverage
Meta-analysis examines cancer risk concern for JAK inhibitors
Although no increased cancer risk was seen vs. methotrexate or placebo, Janus kinase inhibitors were associated with a higher cancer risk than...
Latest News
NPF provides guidance for virtual psoriasis visits
A National Psoriasis Foundation position paper addresses ongoing management of psoriatic disease via telemedicine.
Cosmeceutical Critique
Bergamot
Beyond its niche role in treatments for vitiligo and psoriasis, this botanical product appears to show potential as an anti-inflammatory agent as...
Latest News
Analysis identifies gaps in CV risk screening of patients with psoriasis
Regional variation in screening rates “is not explained by patient demographics or disease severity.”
Feature
Biosimilars and patients: Discussions should address safety, cost, and anxiety about change
Physicians can respond to pushback from patients on switching to a biosimilar by offering resources and discussing options for both biosimilar and...